Greenwich LifeSciences, Inc. - Common stock (GLSI)

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial.

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.

The company’s Board extended the lock-up on shares held by directors, officers, and pre-IPO investors through Sept. 30, 2026.

Let's have a look at the stocks with an unusual volume in today's session.

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01.

Greenwich LifeSciences just reported results for the second quarter of 2024.

GLSI stock results show that Greenwich LifeSciences beat analyst estimates for earnings per share the first quarter of 2024.

GLSI stock results show that Greenwich LifeSciences missed analyst estimates for earnings per share the fourth quarter of 2023.

Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.

Although US stocks closed higher on Tuesday, there were a few notable insider trades.

Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.

Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move.

Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week!